CorMedix (CRMD)
(Delayed Data from NSDQ)
$7.01 USD
-0.24 (-3.24%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $7.00 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
CorMedix Inc [CRMD]
Reports for Purchase
Showing records 21 - 40 ( 101 total )
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Steady March to NDA; Reverse Stock Split Completed
Provider: Roth Capital Partners, Inc.
Analyst: ISAACSON J
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Reverse Stock Split Takes Effect; Adjusting Price Target to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Neutrolin Filing Timeline Perspectives; Reducing Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
FDA Update Indicates Eligibility for Neutrolin Filing Under LPAD Pathway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Full Top-Line LOCK-IT-100 Trial Data Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
LOCK-IT-100 Data Released; FDA Meeting Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Near-Term Neutrolin Regulatory Filing; Finances Shored Up; Raising Target to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
An Anti-Microbial Solution - Initiating with Buy
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Neutrolin Accelerated Approval Remains Likely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2Q18 Financial Results Reported; FDA Meeting Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Neutrolin Interim Analysis Delivers Best Case Scenario; Raising Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R